Curis (NASDAQ:CRIS) Downgraded by Zacks Research to Strong Sell

Curis (NASDAQ:CRIS) was downgraded by investment analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued on Tuesday,Zacks.com reports.

Several other equities research analysts have also weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $43.00 price objective (up from $17.00) on shares of Curis in a report on Friday, July 24th. Wall Street Zen downgraded shares of Curis to a “strong sell” rating in a report on Saturday, August 8th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Curis in a research report on Friday, July 17th. One investment analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Curis has an average rating of “Reduce” and an average target price of $43.00.

Curis Trading Down 27.7%

Curis stock opened at $1.67 on Tuesday. Curis has a 12 month low of $1.63 and a 12 month high of $39.00. The business’s 50 day simple moving average is $6.15 and its 200 day simple moving average is $11.93. The company has a market cap of $3.49 million, a price-to-earnings ratio of -0.07 and a beta of 3.13.

Curis (NASDAQ:CRIS) last released its earnings results on Tuesday, May 12th. The biotechnology company reported ($25.00) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($6.53) by ($18.47). As a group, equities research analysts forecast that Curis will post -33.29 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Curis

Institutional investors have recently made changes to their positions in the stock. Squarepoint Ops LLC lifted its stake in Curis by 17.9% in the 3rd quarter. Squarepoint Ops LLC now owns 59,140 shares of the biotechnology company’s stock worth $98,000 after purchasing an additional 8,973 shares in the last quarter. Jane Street Group LLC grew its position in shares of Curis by 71.8% during the 4th quarter. Jane Street Group LLC now owns 25,323 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 10,586 shares in the last quarter. XTX Topco Ltd purchased a new position in shares of Curis during the 4th quarter valued at $26,000. Maverick Capital Ltd. increased its holdings in shares of Curis by 7.8% in the second quarter. Maverick Capital Ltd. now owns 681,381 shares of the biotechnology company’s stock worth $1,472,000 after purchasing an additional 49,554 shares during the period. Finally, Focused Wealth Management Inc increased its holdings in shares of Curis by 83.4% in the first quarter. Focused Wealth Management Inc now owns 109,746 shares of the biotechnology company’s stock worth $60,000 after purchasing an additional 49,900 shares during the period. Hedge funds and other institutional investors own 29.97% of the company’s stock.

Curis Company Profile

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.